» Articles » PMID: 16731853

The Experimental Type 2 Diabetes Therapy Glycogen Phosphorylase Inhibition Can Impair Aerobic Muscle Function During Prolonged Contraction

Overview
Journal Diabetes
Specialty Endocrinology
Date 2006 May 30
PMID 16731853
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Glycogen phosphorylase inhibition represents a promising strategy to suppress inappropriate hepatic glucose output, while muscle glycogen is a major source of fuel during contraction. Glycogen phosphorylase inhibitors (GPi) currently being investigated for the treatment of type 2 diabetes do not demonstrate hepatic versus muscle glycogen phosphorylase isoform selectivity and may therefore impair patient aerobic exercise capabilities. Skeletal muscle energy metabolism and function are not impaired by GPi during high-intensity contraction in rat skeletal muscle; however, it is unknown whether glycogen phosphorylase inhibitors would impair function during prolonged lower-intensity contraction. Utilizing a novel red cell-perfused rodent gastrocnemius-plantaris-soleus system, muscle was pretreated for 60 min with either 3 micromol/l free drug GPi (n=8) or vehicle control (n=7). During 60 min of aerobic contraction, GPi treatment resulted in approximately 35% greater fatigue. Muscle glycogen phosphorylase a form (P<0.01) and maximal activity (P<0.01) were reduced in the GPi group, and postcontraction glycogen (121.8 +/- 16.1 vs. 168.3 +/- 8.5 mmol/kg dry muscle, P<0.05) was greater. Furthermore, lower muscle lactate efflux and glucose uptake (P<0.01), yet higher muscle Vo(2), support the conclusion that carbohydrate utilization was impaired during contraction. Our data provide new confirmation that muscle glycogen plays an essential role during submaximal contraction. Given the critical role of exercise prescription in the treatment of type 2 diabetes, it will be important to monitor endurance capacity during the clinical evaluation of nonselective GPi. Alternatively, greater effort should be devoted toward the discovery of hepatic-selective GPi, hepatic-specific drug delivery strategies, and/or alternative strategies for controlling excess hepatic glucose production in type 2 diabetes.

Citing Articles

The many metabolic sources of acetyl-CoA to support histone acetylation and influence cancer progression.

Feron O Ann Transl Med. 2020; 7(Suppl 8):S277.

PMID: 32015996 PMC: 6976516. DOI: 10.21037/atm.2019.11.140.


Glycogen phosphorylase inhibition improves beta cell function.

Nagy L, Marton J, Vida A, Kis G, Bokor E, Kun S Br J Pharmacol. 2017; 175(2):301-319.

PMID: 28409826 PMC: 5758390. DOI: 10.1111/bph.13819.


Novel Liver-targeted conjugates of Glycogen Phosphorylase Inhibitor PSN-357 for the Treatment of Diabetes: Design, Synthesis, Pharmacokinetic and Pharmacological Evaluations.

Zhang L, Song C, Miao G, Zhao L, Yan Z, Li J Sci Rep. 2017; 7:42251.

PMID: 28225016 PMC: 5320518. DOI: 10.1038/srep42251.


Glycogen phosphorylase inhibitor N-(3,5-dimethyl-Benzoyl)-N'-(β-D-glucopyranosyl)urea improves glucose tolerance under normoglycemic and diabetic conditions and rearranges hepatic metabolism.

Nagy L, Docsa T, Szanto M, Brunyanszki A, Hegedus C, Marton J PLoS One. 2013; 8(7):e69420.

PMID: 23936011 PMC: 3723905. DOI: 10.1371/journal.pone.0069420.


Restoration of hepatic glycogen deposition reduces hyperglycaemia, hyperphagia and gluconeogenic enzymes in a streptozotocin-induced model of diabetes in rats.

Ros S, Garcia-Rocha M, Calbo J, Guinovart J Diabetologia. 2011; 54(10):2639-48.

PMID: 21811873 DOI: 10.1007/s00125-011-2238-x.